Korting et al
5 |
37/F |
IgG κ |
2 |
Improvement after myeloma therapy |
Doyle et al
6 |
58/F
62/F
|
NA |
4
40
|
NA |
Ohta et al
7 |
64/M |
IgG κ |
11 |
Improvement after myeloma therapy |
Hodak et al
8 |
74/F |
IgG κ |
4 |
Improved after 1.5 years of
melphalan |
Rimon et al
9 |
62/F |
IgG λ |
22 |
NA |
Salisbury et
al10 |
76/F |
IgA κ |
0.1 |
Improvement after 9 months of cyclophosphamide
and prednisolone |
Nakanishi et al
11 |
50/M |
IgG κ |
3 |
NA |
Schmidt et al
12 |
46/M |
IgG λ |
22 |
NA |
Pujol et al
13 |
74/M |
IgA κ |
15 |
Improvement after myeloma therapy |
Valente et al
14 |
56/F |
IgA κ |
6 |
Improvement after melphalan and
prednisolone |
Bachleitner-Hoffman et al
15 |
73/F |
IgG |
24 |
Improvement after vincristine, melphalan,
cyclophosphamide and prednisolone |
Colovic et al
16 |
55/F |
IgG λ |
20 |
Improvement after 6 cycles of endoxan, thalidomide
and dexamethasone |
Smeeta
Gajendra etal 2
|
24/M |
IgA κ |
8 |
Improvement after 9 months of thalidomide and
dexamethasone |